Growth Metrics

Karyopharm Therapeutics (KPTI) Cash from Investing Activities (2016 - 2025)

Karyopharm Therapeutics' Cash from Investing Activities history spans 13 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 66.21% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $43.4 million, down 54.57%, while the annual FY2025 figure was $43.4 million, 54.57% down from the prior year.
  • Cash from Investing Activities reached $5.0 million in Q4 2025 per KPTI's latest filing, up from $4.8 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $51.3 million in Q2 2024 to a low of -$65.3 million in Q4 2022.
  • Average Cash from Investing Activities over 5 years is $9.2 million, with a median of $15.0 million recorded in 2024.
  • Peak YoY movement for Cash from Investing Activities: crashed 312.21% in 2022, then surged 197.25% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $30.8 million in 2021, then plummeted by 312.21% to -$65.3 million in 2022, then surged by 141.11% to $26.8 million in 2023, then tumbled by 44.88% to $14.8 million in 2024, then crashed by 66.21% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Cash from Investing Activities are $5.0 million (Q4 2025), $4.8 million (Q3 2025), and $18.3 million (Q2 2025).